Tagged with

China In 2024, contract manufacturers WuXi Biologics and WuXi AppTec were catapulted into global consciousness as two of five Chinese service providers deemed a US national security threat in a draft for a new BIOSECURE Act.   While the final version of the law, signed by President Donald Trump in December…

USA Kim Moran, SVP & Head of US Rare Disease at UCB, discusses how the company is building on its long-standing heritage in neurology to expand into rare and ultra-rare conditions. She highlights the strategic thinking behind UCB’s growing rare disease portfolio and explains what it takes to successfully bring therapies…

China This week’s China healthcare highlights from PharmaBoardroom content partner Selesta include Trinomab preparing for a STAR Market IPO to raise RMB 1.5 billion for its monoclonal antibody portfolio, including first-in-class TNM002; Huadao Biopharma launching a STAR Market IPO process with its low-cost CAR-T therapy for relapsed non-Hodgkin lymphoma; and Sirius…

China Founded by Dr Helen Yang and Dr Peter He, Oricell Therapeutics stands at the forefront of next-generation cell and gene therapy innovation. Built on a comprehensive platform that integrates antibody discovery, CAR-T engineering, and advanced manufacturing, Oricell is advancing differentiated therapies for solid tumours such as hepatocellular carcinoma and hematologic…

Taiwan Dr Chen-Yu Cheng, founder and chairman at Formosa Laboratories & Pharmaceuticals, is leading a strategic transition from generic API manufacturing toward high- value CDMO services and innovative drug development. By leveraging proprietary nanotechnology and antibody-drug conjugate platforms, the group is diversifying into injectables and considering the US market. Dr Cheng…

USA Paul Kim, a leading FDA attorney and policy expert formerly at both the FDA and the US Congress, discusses the current shifts within the American life sciences and regulatory landscape. Kim examines the prevailing sentiment of the industry amidst a period of significant structural upheaval and regulatory whiplash. He offers…

USA After 25 years at Genzyme and Sanofi, Chris Hwang joined a biotech startup in China in 2016 to develop advanced bioprocessing technologies that reduce cost of goods while maintaining reliable supply. As CTO of Transcenta, he and his team have advanced continuous bioprocessing, delivering dramatic productivity improvements over traditional batch…

USA Christine Baeder, President of USA and LATAM at Apotex, discusses the company’s evolution following private equity investment, its Generics Plus strategy, and the critical role of the US market. She highlights supply chain resilience, the challenges facing biosimilar adoption, and the need for structural policy reforms to sustain affordability, innovation…

USA Craig Martin, CEO of the Orphan Therapeutics Accelerator (OTXL), discusses the urgent need for a new business model to rescue abandoned clinical-stage programs in the rare disease sector. He details OTXL’s innovative non-profit model, which leverages a collaborative network of partners and unique tax-exempt incentives to liberate stranded assets from…

Europe Rainer Westermann offers a sobering take on Europe’s declining global status as both a source and recipient of biopharmaceutical innovation. He argues that the time for a paradigm shift in how the EU values innovation is now, calling for pricing system reform, speedier regulatory and HTA procedures, manufacturing investments, and…

Taiwan Siegfried Gschliesser, co-founder and CEO of Anya Biopharm, has spent over two decades shaping the pharmaceutical landscape in Asia. Under his guidance, Anya has pioneered a proprietary oral peptide delivery platform, leveraging capital-efficient strategies and Taiwan’s robust talent pool to challenge global standards in metabolic health and chronic disease management.  …

China Suzhou’s bioBAY has emerged as one of China’s most dynamic biotechnology clusters, bringing together hundreds of biotech and medtech companies within an ecosystem designed to support the full innovation cycle, from early discovery to global partnerships. In this conversation, CEO Michael Yin reflects on how the park has evolved alongside…